WELIREG® (belzutifan) Gains First European Commission Approval for Two Indications

WELIREG® (belzutifan) Gains First European Commission Approval for Two Indications Merck (NYSE: MRK), known as MSD outside the United States and Canada, has announced that the European Commission (EC) has conditionally approved WELIREG® (belzutifan), an oral hypoxia-inducible factor-2 alpha (HIF-2α)…










